A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
A phase 2 trial of Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by Elpiscience (Suzhou) Biopharma, Ltd., now recruiting.
Overview
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06623136 by Elpiscience (Suzhou) Biopharma, Ltd., with 40 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: ES102, Toripalimab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Phase
Phase 2
Sponsor
Elpiscience (Suzhou) Biopharma, Ltd.
Registry
Enrolled
40